[Malignant hyperthermia. The ugly]

Area of Science:

• Anesthesiology
• Pharmacology
• Genetics

Context:

• Malignant hyperthermia (MH) is a severe, potentially fatal reaction to certain anesthetic agents.
• It is primarily linked to genetic defects in the ryanodine receptor subtype 1.
• Other conditions like myotonias and muscular dystrophies can also trigger MH-like symptoms.

Purpose:

• To define malignant hyperthermia (MH) as a clinical syndrome.
• To elucidate the underlying pathophysiology involving calcium release in muscle cells.
• To highlight diagnostic and therapeutic considerations in perioperative care.

Summary:

• MH presents as a spectrum of severity, from mild to life-threatening crises, triggered by specific substances or mechanisms.
• The core issue is excessive calcium release into skeletal muscle cytoplasm, often due to genetic defects.
• While perioperative MH is treatable with current knowledge, atypical presentations and non-anesthetic triggers pose diagnostic challenges.

Impact:

• Improved understanding of MH pathophysiology aids in accurate diagnosis and timely intervention.
• Awareness of atypical triggers and non-hospital settings is vital for preventing misdiagnosis.
• Distinguishing MH from similar syndromes like neuroleptic malignant syndrome and serotonin syndrome is critical for patient outcomes.